Drug licensing deal brings millions in Israeli capital to Burnaby

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to ...

Israel’s Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that it will pay Burnaby-based Xenon Pharmaceuticals Inc. up to $376 million for a worldwide license to a pain drug that Xenon is developing.

The deal will see Teva pay Xenon $41 million up front, and then fund up to $335 million in “development, regulatory and sales-based milestones” for Xenon’s drug, XEN402. For its investment, Teva will obtain an exclusive worldwide license for the drug. Xenon will be entitled to royalties payable on sales and an option to participate in commercialization in the U.S.

Jeremy Levin, president and CEO of Teva, welcomed the deal.

“[This drug] holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain,” he said. “In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.”

Simon Pimstone, president and CEO of Xenon, also expressed satisfaction with the deal.

“This partnership with Teva,” he said, “is Xenon’s seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.”

The drug is currently in clinical development.

jwagler@biv.com

@JennyWagler_BIV

comments powered by Disqus

More from Technology

BC Tech touts Cascadia links ahead of federal government’s skilled foreign workers ...

Association venturing to Seattle to draw more technology talent north

Read Article

SFU Surrey researcher tests tool to help at-risk youth

Mental health treatment aimed at assisting Lower Mainland’s largest youth population

Read Article

BIV on Global BC May 18, 2017: Trudeau at Microsoft summit; Housing ...

Hayley Woodin discusses Trudeau promoting Canadian tech at Microsoft summit. Plus: What are the chances of Canada's housing market going bust?

Read Article

Vancouver biotech Novelogics partners with CDRD to advance cancer treatment

Read Article

Body heat: Young tech workers drive market migration

Vancouver technology companies find employees want to be close to where their peers are – and, increasingly, that is not in a shiny downtown office ...

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×